These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 6705456)
1. Disposition of oral lisuride in Parkinson's disease. Burns RS; Gopinathan G; Hümpel M; Dorow R; Calne DB Clin Pharmacol Ther; 1984 Apr; 35(4):548-56. PubMed ID: 6705456 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. Krause W; Dorow R; Nieuweboer B; Hasan SH Eur J Clin Pharmacol; 1984; 27(3):335-9. PubMed ID: 6510462 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral terguride in patients with a prolactinoma. Lapka R; Marek J; Rejholec V; Franc Z Eur J Clin Pharmacol; 1986; 30(3):363-5. PubMed ID: 3732377 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey. Humpel M; Toda T; Oshino N; Pommerenke G Eur J Drug Metab Pharmacokinet; 1981; 6(3):207-19. PubMed ID: 7308240 [TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. Hümpel M; Krause W; Hoyer GA; Wendt H; Pommerenke G Eur J Drug Metab Pharmacokinet; 1984; 9(4):347-57. PubMed ID: 6532807 [TBL] [Abstract][Full Text] [Related]
6. Lisuride in Parkinson's disease. Schachter M; Blackstock J; Dick JP; George RJ; Marsden CD; Parkes JD Lancet; 1979 Nov; 2(8152):1129. PubMed ID: 91855 [No Abstract] [Full Text] [Related]
7. Pharmacokinetics of lisuride after subcutaneous infusion. Krause W; Nieuweboer B; Ruggieri S; Stocchi F; Suchy I J Neural Transm Suppl; 1988; 27():71-4. PubMed ID: 3165439 [TBL] [Abstract][Full Text] [Related]
8. The use of lisuride in severe Parkinson's disease. Chin D; Yu YL; Huang CY Clin Exp Neurol; 1986; 22():63-9. PubMed ID: 3581512 [TBL] [Abstract][Full Text] [Related]
9. [Oral lisuride in Parkinson's disease]. Obeso JA; Luquin MR; Martínez Lage JM Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822 [No Abstract] [Full Text] [Related]
10. Therapeutic effect of lisuride in advanced Parkinson's disease. Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126 [TBL] [Abstract][Full Text] [Related]
11. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease. Obeso JA; Luquin MR; Martínez Lage JM Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037 [TBL] [Abstract][Full Text] [Related]
12. Lisuride and pergolide in Parkinson's disease. Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769 [No Abstract] [Full Text] [Related]
18. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. LeWitt PA; Burns RS; Calne DB Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586 [TBL] [Abstract][Full Text] [Related]
19. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Vaamonde J; Luquin MR; Obeso JA Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647 [TBL] [Abstract][Full Text] [Related]
20. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist. Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052 [No Abstract] [Full Text] [Related] [Next] [New Search]